Oct. 21, 2025, مقالات ISI
Imeglimin, a novel oral antidiabetic belonging to the “glimin” class, has emerged as a promising therapeutic option for Type 2 Diabetes Mellitus (T2DM). It exerts dual effects by improving insulin secretion and enhancing mitochondrial function. This umbrella review, systematic review, and meta-analysis aimed to comprehensively assess the efficacy and safety of imeglimin in the management of T2DM.
A systematic literature search was performed in PubMed, Scopus, Web of Science, Embase, and Cochrane Central up to June 2025. Randomized controlled trials (RCTs) with follow-up durations ≥12 weeks were included. Outcomes of glycemic control, insulin sensitivity, β-cell function, and lipid profiles were analyzed using random- or fixed-effects models depending on heterogeneity. Quality assessment was performed via the Cochrane Risk of Bias 2.0 tool, AMSTAR2, and evidence strength was rated using the GRADE framework.
Twelve RCTs (n = 1,774 participants) were identified. Imeglimin significantly decreased fasting plasma glucose (FPG) (SMD: −0.51; 95% CI: −0.72, −0.29; p < 0.001) and glycated hemoglobin (HbA1c) (SMD: −0.45; 95% CI: −0.86, −0.05; p = 0.031), and improved β-cell function (HOMA-β) (SMD: 0.59; 95% CI: 0.18, 1.01; p = 0.020). No significant changes were observed in insulin, HOMA-IR, or C-peptide levels (p > 0.05). LDL-cholesterol slightly increased (SMD: 0.32; 95% CI: 0.11, 0.53; p = 0.017), while HDL-C and triglycerides were unaffected. Safety analyses showed no significant differences in serious or non-serious adverse events between imeglimin and control groups.
Imeglimin demonstrates favorable efficacy for glycemic control and β-cell function, with an acceptable safety profile in adult T2DM patients. However, a mild LDL-C increase warrants further investigation. Large-scale, long-term clinical trials across diverse populations are required to confirm these outcomes.
Imeglimin; Type 2 diabetes mellitus; Glycemic control; β-cell function; Systematic review; Meta-analysis.
Ginseng supplementation may improve inflammatory profiles and support cardiometabolic health, according to a comprehensive review of 44 randomized controlled trials.
Nigella sativa supplementation significantly improves lipid profiles in adults by lowering TC, TG, LDL-C, and raising HDL-C, supporting its role as an adjuvant anti-hyperlipidemic agent.
Most Iranian hospital pharmacies fall short of age-friendly criteria, stressing the urgency for policy and system reforms to meet elderly patients’ needs.
Nigella sativa supplementation effectively reduces fasting blood sugar (FBS) and HbA1c levels in adults, though its effects on insulin and HOMA-IR are inconclusive.
Curcumin supplementation appears to alleviate anxiety symptoms, but more high-quality trials are needed to confirm its clinical effectiveness.
Ghee may support bone and joint health through fatty acids and vitamins that reduce inflammation, enhance bone density, and improve joint lubrication.
Glucomannan supplementation reduces total cholesterol and LDL-C in adults, with no significant effects on TG, HDL-C, or Apo A1 levels
Berberine supplementation shows significant benefits in improving lipid profile (reducing LDL-C, TC, TG, and increasing HDL-C) and waist circumference, though its effects on overall obesity indices remain inconclusive.
An Evidence-Based Review on Wound Healing Herbal Remedies From Reports of Traditional Persian Medicine
A scientific report on a novel herbal cream for skin wound healing, combining traditional Persian botanical knowledge with modern pharmaceutical research.
This meta-analysis evaluates how walnut intake influences key oxidative stress biomarkers, highlighting increased catalase activity with no significant changes in other markers.
